titleOfInvention |
Sustained release dosage form comprising ruxolitinib or its salt, janus kinase inhibitor (jak); and method to treat a disease associated with the activity of jak such as an autoimmune disease, a skin disorder, allograft rejection, multiple sclerosis and rheumatoid arthritis, among others. |